Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07557602
PHASE1

mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults

Sponsor: Vaccine Company, Inc.

View on ClinicalTrials.gov

Summary

This is an adaptive design Phase 1 clinical trial to evaluate the safety and immunogenicity of VXCO-102 in healthy adult participants.

Official title: A Phase 1, Dose Escalation, Placebo-Controlled, Adaptive-Design Study to Evaluate the Safety and Immunogenicity of VXCO-102, a mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults

Key Details

Gender

All

Age Range

18 Years - 25 Years

Study Type

INTERVENTIONAL

Enrollment

45

Start Date

2026-05-04

Completion Date

2027-08-31

Last Updated

2026-04-29

Healthy Volunteers

Yes

Conditions

Interventions

BIOLOGICAL

VXCO-102

Sterile liquid for injection

BIOLOGICAL

Placebo

0.9% sodium chloride (BP grade)

Locations (2)

Q-Pharm Pty Ltd/Nucleus Network Pty Ltd

Herston, Queensland, Australia

Nucleus Network Pty Ltd

Melbourne, Victoria, Australia